Recce Pharmaceuticals Ltd., a company developing a new class of synthetic anti-infectives, announced the successful batch completion under Good Manufacturing Practices (GMP) for its lead candidate, RECCE 327 (R327), with the company’s manufacturing process now producing 5,000 GMP doses of R327 per week.   “We are thrilled to announce the successful batch completion of human pharmaceutical grade R327, representing a crucial step forward in our mission to address the global threat of antim...